All relevant data are available on Figshare: <https://figshare.com/articles/PlGF_and_Sleep_Apnea/2113396/1>.

Introduction {#sec006}
============

Recent data suggest that obstructive sleep apnea (OSA) is underdiagnosed in patients after acute myocardial infarction (AMI) \[[@pone.0147686.ref001]\]. Intermittent episodes of hypoxia and arousals cause an increase in sympathetic activity, oxidative stress, hypercoagulability and cardiac hyperexcitability that could aggravate the severity of AMI and worsen the short-term prognosis of OSA patients \[[@pone.0147686.ref002]--[@pone.0147686.ref004]\]. Nevertheless, a cardioprotective role of OSA in the context of AMI, via ischemic preconditioning, has also been postulated \[[@pone.0147686.ref005]\]. Such protection would require the activation of adaptive mechanisms, such as increased recruitment of proliferative and angiogenic endothelial progenitor cells \[[@pone.0147686.ref006]\].

With the emergence of novel biomarkers, it may be feasible to characterize different aspects of the pathophysiology of acute coronary syndrome (ACS) \[[@pone.0147686.ref007];[@pone.0147686.ref008]\]. Placental growth factor (PlGF), a member of the vascular endothelial growth factor family (VEGF), is expressed in cells of the cardiovascular system and plays a predominant role in pathological angiogenesis without affecting quiescent vessels in healthy organs \[[@pone.0147686.ref009];[@pone.0147686.ref010]\]. PlGF expression increases in the damaged human heart, and PlGF levels in blood increase after AMI \[[@pone.0147686.ref011]\]. Elevated PlGF levels have emerged as an important, independent marker of short-term adverse outcomes in patients with ACS \[[@pone.0147686.ref012]\]. In contrast, PlGF plasma levels in the acute phase after myocardial infarction (MI) have been found to be positively correlated with the degree of improvement in left ventricular function that occurs during the chronic phase of MI; this finding suggests that PlGF may be involved in repairing injured myocardial tissue \[[@pone.0147686.ref013]\]. Cardiac PlGF expression is induced by hypoxia, and it has been suggested that PlGF is a stress-response factor that suppresses pathological remodeling in the heart by inducing angiogenesis, cardiomyocyte growth and peripheral mobilization of mononuclear cells and bone marrow-derived stem cells towards ischemic myocardial tissue \[[@pone.0147686.ref011]\]. Recent evidence demonstrates that PlGF is a crucial mediator of adaptive cardiac remodeling after myocardial infarction, and it has been suggested that the effects of PlGF could form the basis of a potential therapeutic strategy in the future \[[@pone.0147686.ref014]\].

The purpose of this study was to assess the impact of OSA on circulating PlGF levels in patients with ACS and to determine whether PlGF levels have short-term prognostic significance in patients with OSA compared with patients without OSA.

Materials and Methods {#sec007}
=====================

Patients {#sec008}
--------

The Ethics Committee of each participating center approved the study: the Comitè Ètic d'Investigació (Hospital Universitari Son Espases, Palma), the Comité Ético de Investigación Clínica de Euskadi (Hospital de Cruces, Bilbao), the Comité Ético de Investigación Clínica (Hospital Arnau de Vilanova i Santa Maria, Lleida), the Comitè Ètic d'Investigació Clínica (Hospital Germans Trias i Pujol, Barcelona), the Comité Ético de Investigación Clínica (Hospital General Universitario de Guadalajara, Guadalajara), the Comitè Ètic d'Investigació Clínica (Hospital Parc Taulí, Sabadell), the Comité Ético de Investigación Clínica de Burgos y Soria (Hospital General Yagüe, Burgos), and the Comitè Ètic d'Investigació Clínica (Hospital Clínic, Barcelona). All patients provided written, informed consent.

This is an ancillary study of the ISAACC Study (NCT01335087), a multicenter, open-label, parallel, prospective, randomized, controlled trial \[[@pone.0147686.ref015]\]. The ISAACC study is evaluating the effects of CPAP treatment on the incidence of new cardiovascular events in patients with an episode of ACS and OSA. The ISAACC study includes non-sleepy patients because it is unethical to fail to treat OSA patients with excessive daytime sleepiness. The first patient was included in April 2011, so in spite of newer guidelines regarding the sleep apnea definitions \[[@pone.0147686.ref016]\], the recruitment of patients was consistent as originally established for ISAACC, and published elsewhere \[[@pone.0147686.ref015];[@pone.0147686.ref017]\]. For the present study, we included 538 patients (men and women age ≥18 years old) who were admitted for ACS to coronary care units or cardiology hospitalization wards from fourteen teaching hospitals in Spain. A polygraphic study was performed during the first 48--72 h after admission. The case (n = 312) or control (n = 226) status of each ACS patient was defined using an apnea-hypopnea index (AHI) threshold of 15 or greater. ACS was defined as the acute presentation of coronary disease, with or without ST-elevation, unstable angina, or MI type 1 \[[@pone.0147686.ref017]\]. The exclusion criteria for this study were the following: previous CPAP treatment; psychophysical inability to complete questionnaires; the presence of any previously diagnosed sleep disorder; \>50% of apneas consisting of central apneas or the presence of Cheyne-Stokes respiration; the presence of daytime sleepiness (Epworth Sleep Scale \[ESS\] score \>10); the presence of chronic diseases, including neoplasms, renal insufficiency (GFR\<15 mL/min/1.73 m^2^), severe COPD (FEV~1~\<50%), chronic depression, and other limiting chronic diseases; a medical history that could interfere with the objectives of the study; and any processes, whether cardiovascular or otherwise, that reduced life expectancy to \<1 year; and patients in cardiogenic shock.

Procedures {#sec009}
----------

The diagnosis of OSA was based on the results of a sleep test, in accordance with the guidelines of the Spanish national consensus on apnea-hypopnea syndrome \[[@pone.0147686.ref018]\]. All participating centers used the same model of polygraph (Embletta; ResMed, Australia) for the diagnosis of OSA. Oronasal flow, thoracoabdominal movements, ECG, and pulse oximetry were recorded. Apnea is defined as an absence of airflow lasting ≥10 seconds. Hypopnea is defined as a reduction in airflow lasting ≥10 seconds and is associated with oxygen desaturation. Oxygen desaturation (ODI) is considered as a decrease in SaO2 \>4%. The apnea-hypopnea index is defined as the number of apneas and hypopneas per hour of sleep. The extent of self-reported sleepiness/drowsiness was analyzed using the Spanish version of the ESS test \[[@pone.0147686.ref019]\]. Echocardiographic evaluations and Killip classification were performed routinely at hospital admission. During hospitalization, we evaluated the severity of ACS and each patient's short-term prognosis, in terms of the ejection fraction, the Killip score, the number of affected vessels, the average and peak troponin levels, and complications related to the cardiovascular event itself (heart failure, reinfarction, mechanic complications such myocardial rupture, arrhythmia and stroke) and mortality. Other complications related to the ICU admission were excluded, such as infections or venous thrombosis following immobilization, since they were not due to the cardiovascular event for which the patient was admitted.

Blood sampling and analysis {#sec010}
---------------------------

Peripheral blood samples were collected from all subjects after the polygraphic study at the time of randomization. Plasma and serum samples were stored at -80°C until analysis. Cardiac marker levels were measured by investigators who were blinded to the patients' histories. Blood chemistry data were measured using commercially available assays. PlGF levels were measured in plasma using an enzyme-based electrochemiluminescence assay (Roche Diagnostics, Germany). The lower limit of detection was 3 pg/mL, and the upper limit of detection was 10.000 pg/mL. The intra-assay coefficient of variation was 1.1%, and the inter-assay coefficient of variation 2.6%.

Data analysis {#sec011}
-------------

Data on the patients included in this study were incorporated into a password-protected database. The mean values (and standard deviations) or frequencies (and percentages) were computed to evaluate the differences between the control and OSA patients, and the significance of differences was assessed using Mann-Whitney tests (or t tests, if data were normally distributed) or chi-squared tests, respectively. OSA patients were divided into 3 groups according to AHI, and the Kruskal-Wallis test was used for comparisons among groups. Spearman´s rank correlations were calculated to assess correlations. The associations among PlGF levels, OSA, and variables related to the severity of ACS were assessed using the Mann-Whitney or chi-squared tests and linear or logistic regression models, as appropriate. Additionally, the models were adjusted for smoking status (current or former smoker vs non-smoker), body mass index, age, gender (male vs female), hypertension, diabetes and dyslipidemia.

Odds ratios, their corresponding 95% confidence intervals, and p-values were calculated using logistic regression models; adjusted p-values were also computed. The threshold for statistical significance was set at p\<0.05. SPSS v19 software (IBM Corp., Armonk, NY) was used for all analyses.

Results {#sec012}
=======

The clinical and sleep-related characteristics of the patients are given in [Table 1](#pone.0147686.t001){ref-type="table"}.

10.1371/journal.pone.0147686.t001

###### Anthropometric, clinical and biochemical variables for patients with obstructive sleep apnea (OSA) and controls.

![](pone.0147686.t001){#pone.0147686.t001g}

                                 Controls(n = 226)   OSA(n = 312)   p-value
  ------------------------------ ------------------- -------------- ---------
  Age, years                     56.5±11.5           61.2±10.3      \<0.001
  Male, %                        191 (84.5%)         250 (80.1%)    0.192
  AHI, h^-1^                     6.3±4.1             35.7±1 7.4     \<0.001
  ODI, h^-1^                     9.3±17.9            24.9±16.9      \<0.001
  Mean SaO2, %                   93.6±2.2            92.7±2.2       \<0.001
  Min SaO2, %                    86.7±5.2            82.1±7.2       \<0.001
  Time with SaO2 \<90%, %        4.2±11.5            11.2±18.0      \<0.001
  BMI, kg•m^-2^                  26.1±6.1            28.3±6.2       \<0.001
  Glucose, mg/dL                 119±53              128±59         0.078
  HDL cholesterol, mg/dL         45±30               40±18          0.058
  LDL cholesterol, mg/dL         116±41              110±33         0.103
  Triglyceride, mg/dL            154±117             141±79         0.161
  Hypertension                   87 (38.5%)          178 (57.1%)    \<0.001
  Diabetes mellitus              50 (22.1%)          83 (26.6%)     0.243
  Dyslipidemia                   108 (47.8%)         134 (42.9%)    0.265
  Smoker                                                            0.163
  No                             57 (25.2%)          103 (32.8%)    
  Yes                            107 (47.3%)         134 (42.7%)    
  Former smoker                  62 (27.4%)          77 (24.5%)     
      Diuretics                  28 (12.5%)          67 (21.4%)     0.008
  Anticoagulants                 6 (2.7%)            22 (7.1%)      0.025
  Antacids                       47 (20.9%)          96 (30.8%)     0.011
  Hypolipidemic agents           68 (30.4%)          126 (40.4%)    0.017
      β-blockers                 44 (19.8%)          77 (24.7%)     0.186
  Calcium antagonists            9 (4.0%)            44 (14.2%)     \<0.001
  ACEIs                          14 (18.9%)          29 (22.5%)     0.050
  Insulin                        10 (4.5%)           29 (9.3%)      0.034
      Oral antidiabetic agents   37 (16.5%)          61 (19.6%)     0.361
      Bronchodilators            16 (7.1%)           12 (3.8%)      0.091

Values represent the percentage of the patients and control subjects or means ± standard deviations. AHI, apnea-hypopnea index; ODI, oxygen desaturation index; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEIs, angiotensin-converting enzyme inhibitors.

OSA was detected in 58% of the study subjects (312 patients and 226 controls).

Patients with OSA were significantly older and had higher BMIs compared with those without OSA. No difference was detected between genders ([Table 1](#pone.0147686.t001){ref-type="table"}). The number of hypertensive patients was significantly higher in the OSA group ([Table 1](#pone.0147686.t001){ref-type="table"}). The number of patients who took antihypertensive drugs, particularly diuretics and calcium agonists, was higher in the OSA group.

PlGF levels were higher in patients with OSA compared with patients without OSA (19.9 pg/mL, interquartile range: 16.6--24.5 pg/mL; 18.5 pg/mL, interquartile range: 14.7--22.7 pg/mL; p\<0.001).

PlGF levels were correlated with age (r = 0.304, p\<0.001), AHI (r = 0.142, p = 0.001), Min SaO~2~ (r = -0.091, p = 0.038), ODI (r = 0.128, p = 0.004), troponin concentration (r = 0.171, p\<0.001) and mean peak troponin level (r = 0.161, p = 0.001). To investigate the strength of the association between PlGF levels and OSA severity, patients were classified into 3 groups according to AHI. The results showed that PlGF levels increased with AHI even after adjustment. PlGF levels were statistically different among the three groups and higher in the AHI≥30 group (19.9 pg/mL, interquartile range: 17.5--24.8) than both the AHI 15--29.9 group (19.3 pg/mL, interquartile range: 16.2--23.5) and the AHI≤15 group (18.2 pg/mL, interquartile range: 14.7--22.1); (p\<0.003; [Fig 1](#pone.0147686.g001){ref-type="fig"}).

![Levels of PlGF according to AHI groups.\
Error bars represent 95% confidence intervals. The Kruskal-Wallis test was used for comparisons among groups.](pone.0147686.g001){#pone.0147686.g001}

To further assess the associations of variables related to sleep and to the severity of ACS with PlGF levels, we classified the study participants into two groups according to PlGF concentrations ([Table 2](#pone.0147686.t002){ref-type="table"}). A cutoff value of 20 pg/mL for PlGF levels was used based on prior studies \[[@pone.0147686.ref020]\]. Using this cut-off value, we found that up to 156 patients with OSA had PlGF levels \>20, which represent 63.7% of patients with PlGF ≥20 pg/mL. By contrast, the number of non-OSA patients with PlGF levels ≥20 pg/mL was 81, which represent 36.3% of patients with PlGF ≥20 pg/mL.

10.1371/journal.pone.0147686.t002

###### Baseline patient characteristics and variables related to the severity of acute coronary syndrome according to PlGF status.
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                                                                         PlGF\<20 pg/mL(n = 301)   PlGF≥20 pg/mL(n = 237)   p-value
  ---------------------------------------------------------------------- ------------------------- ------------------------ ---------
  Age, years                                                             57.0 ± 11.0               61.8 ± 10.5              \<0.001
  Male, %                                                                245(81.9%)                192 (81.6%)              0.927
  OSA                                                                    160 (53.3%)               156 (63.7%)              0.015
  BMI, kg•m^-2^                                                          27.3 ± 6.3                27.5 ± 6.2               0.653
  Hypertension                                                           135 (44.7%)               132 (55.2%)              0.015
  Diabetes mellitus                                                      71 (23.6%)                61 (25.7%)               0.565
  Dyslipidemia                                                           167 (55.5%)               129 (54.4%)              0.808
  Smoker                                                                                                                    0.138
  No                                                                     86 (28.5%)                75 (31.5%)               
  Yes                                                                    147 (48.7%)               96 (40.3%)               
  Former smoker                                                          69 (22.8%)                67 (28.2%)               
  Number of diseased vessels ≥3                                          48 (17.6%)                65 (30.2%)               \<0.001
  Killip score \>1                                                       12 (5.0%)                 23 (12.9%)               0.004
  Ejection fraction \<51.5%[\*](#t002fn002){ref-type="table-fn"}         58 (25.8%)                40 (23.4%)               0.586
  Peak troponin level≥724.5 ng/mL[\*](#t002fn002){ref-type="table-fn"}   57 (24.4%)                45 (26.0%)               0.704
  CV complications during hospitalization                                16 (5.15%)                23 (9.2%)                0.059

PlGF, placental growth factor; OSA, obstructive sleep apnea; BMI, body mass index; CV, cardiovascular.

\*Optimal threshold to discriminate between OSA and control patients \[[@pone.0147686.ref016]\].

There were no differences in the trend for the ACS category and OSA (unstable angina was present in 14.8% of controls and 13.3% of OSA; NSTEMI in 42.6% of controls and 41.5% of OSA; STEMI in 42.6% of controls and 45.2% of OSA). No significant association was detected between ACS category and PlGF levels.

Patients with elevated PlGF levels were more frequently older and hypertensive, and with respect to ACS severity, the percentages of patients with Killip score \>1 and with 3 or more diseased vessels were higher in the high-PlGF group ([Table 2](#pone.0147686.t002){ref-type="table"}).

In a multivariable analysis, PlGF, together with all baseline characteristics that were found to be predictive in univariate analyses, persisted as independent predictors of severity and short-term outcome (Tables [3](#pone.0147686.t003){ref-type="table"} and [4](#pone.0147686.t004){ref-type="table"}). Patients with higher levels of PlGF had increased odds ratios for a Killip classification \>1 ([Table 3](#pone.0147686.t003){ref-type="table"}, ORs 3.13, p = 0.009; and ORs 2.67, p = 0.011) and for the presence of 3 or more diseased vessels ([Table 4](#pone.0147686.t004){ref-type="table"}, ORs 2.02, p = 0.001; and ORs 1.85, p = 0.009) even after adjustment.

10.1371/journal.pone.0147686.t003

###### Multivariate adjusted odds ratios for Killip score \>1.
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                   OR (95% CI) Not adjusted   p-value   OR (95% CI) Multivariate model[^1^](#t003fn001){ref-type="table-fn"}   p-value   OR (95% CI) Multivariate model[^2^](#t003fn002){ref-type="table-fn"}   p-value
  ---------------- -------------------------- --------- ---------------------------------------------------------------------- --------- ---------------------------------------------------------------------- ---------
  Age              1.04 (1.01--1.08)          0.013     1.01 (0.97--1.05)                                                      0.576     1.01 (0.97--1.05)                                                      0.593
  Gender           0.53 (0.24--1.15)          0.107     0.63 (0.26--1.55)                                                      0.314     0.63 (0.26--1.54)                                                      0.309
  Smoking          0.54 (0.26--1.09)          0.087     0.85 (0.36--1.99)                                                      0.702     0.89 (0.38--2.09)                                                      0.781
  BMI              1.00 (0.95--1.06)          0.906     0.98 (0.93--1.04)                                                      0.547     0.98 (0.93--1.03)                                                      0.456
  Hypertension     3.82 (1.69--8.62)          0.001     2.59 (1.02--6.56)                                                      0.045     2.32 (0.90--5.97)                                                      0.080
  Diabetes         2.47 (1.22--5.03)          0.012     1.79 (0.82--3.89)                                                      0.141     1.80 (0.82--3.92)                                                      0.143
  Dyslipidemia     1.43 (0.70--2.88)          0.325     1.07 (0.51--2.27)                                                      0.858     1.11 (0.52--2.37)                                                      0.787
  OSA              2.07 (0.97--4.41)          0.060     \-                                                                     \-        1.83 (0.80--4.20)                                                      0.155
  PlGF ≥20 pg/mL   3.13 (1.34--7.34)          0.009     2.67 (1.25--5.69)                                                      0,011     2.70 (1.26--5.77)                                                      0.011

^1^ Multivariate model adjusted for age, gender (male vs female), smoking (current or former smoker vs non-smoker), BMI, hypertension, diabetes, dyslipidemia.

^2^ Multivariate model adjusted for age, gender (male vs female), smoking (current or former smoker vs non-smoker), BMI, hypertension, diabetes, dyslipidemia and OSA.

10.1371/journal.pone.0147686.t004

###### Multivariate adjusted odds ratios for ≥3 diseased vessels.
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                        OR (95% CI) Not adjusted   p-value   OR (95% CI) Multivariate model[^1^](#t004fn001){ref-type="table-fn"}   p-value   OR (95% CI) Multivariate model[^2^](#t004fn002){ref-type="table-fn"}   p-value
  --------------------- -------------------------- --------- ---------------------------------------------------------------------- --------- ---------------------------------------------------------------------- ---------
  Age                   1.03 (1.01--1.05)          0.005     1.02 (0.99--1.04)                                                      0.213     1.01 (0.99--1,04)                                                      0.264
  Gender                1.94 (1.01--3.72)          0.047     2.84 (1.38--5.83)                                                      0.005     2.86 (1.39--5.90)                                                      0.004
  Smoking               0.66 (0.42--1.04)          0.073     0.70 (0.42--1.16)                                                      0.168     0.70 (0.42--1.17)                                                      0.172
  BMI                   1.02 (0.98--1.06)          0.390     1.02 (0.98--1.06)                                                      0.461     1.01 (0.97--1.06)                                                      0.541
  Hypertension          2.27 (1.47--3.50)          \<0.001   1.60 (0.96--2.67)                                                      0.070     1.56 (0.93--2.62)                                                      0.088
  Diabetes              2.78 (1.77--4.38)          \<0.001   2.27 (1.38--3.75)                                                      0.001     2.27 (1.37--3.74)                                                      0.001
  Dyslipidemia          1.61 (1.05--2.48)          0.030     1.34 (0.84--2.15)                                                      0.219     1.35 (0.84--2.16)                                                      0.213
  OSA                   1.57 (1.01--2.40)          0.045     \-                                                                     \-        1.25 (0.77--2.03)                                                      0.367
  PlGF level ≥20 ng/L   2.02 (1.32--3.10)          0.001     1.85 (1.16--2.94)                                                      0.009     1.83 (1.15--2.91)                                                      0.011

^1^ Multivariate model adjusted for age, gender (male vs female), smoking (current or former smoker vs non-smoker), BMI, hypertension, diabetes, dyslipidemia.

^2^ Multivariate model adjusted for age, gender (male vs female), smoking (current or former smoker vs non-smoker), BMI, hypertension, diabetes, dyslipidemia and OSA.

The number of cardiovascular complications (heart failure, reinfarction, mechanic complications, arrhythmia and stroke) tended to be higher in the high-PlGF group. However, the multivariate analysis revealed that despite the fact that patients with OSA had high PlGF levels, when assessing the associations between these ACS severity-related variables and high PlGF levels, there were no statistically significant differences after adjustment for OSA ([Table 3](#pone.0147686.t003){ref-type="table"} and [Table 4](#pone.0147686.t004){ref-type="table"}). In addition, no significant interactions were seen between PlGF levels and the effect of OSA with respect to other clinical outcomes such as the length of stay in the coronary unit, length of hospitalization, ejection fraction, number of stents implanted or peak of troponin (p\>0.05).

Discussion {#sec013}
==========

The results of this study show that in patients with ACS, elevated plasma levels of PlGF are associated with the presence of OSA and with adverse outcomes during short-term follow-up. The present findings suggest that the presence of OSA may affect the clinical significance of PlGF in patients with ACS.

PlGF is an established prognostic marker in ACS. However, no study has specifically examined its prognostic capabilities in OSA patients with ACS.

In a previous study, we observed that OSA influences the severity of ACS and its short-term prognosis. OSA was correlated with an increase in peak plasma troponin levels, with the number of diseased vessels and with the length of stay in the coronary unit \[[@pone.0147686.ref017]\]. In this study, we observed that in patients with ACS, higher PlGF levels were associated with adverse short-term outcomes (greater numbers of diseased vessels, higher Killip scores and a tendency to develop more cardiovascular complications). These observations suggest that different pathophysiological mechanisms may be responsible for the expression of PlGF in patients with and without OSA and that these mechanisms may affect short- and long-term risks after ACS in different ways.

PlGF, a member of the VEGF family of angiogenic proteins, plays an important role in pathological angiogenesis \[[@pone.0147686.ref021]\]. Although PlGF and VEGF activate similar signaling pathways, PlGF exhibits greater disease-specific activity than VEGF does, while it does not affect quiescent vessels in healthy tissues. In addition to enhancing angiogenesis, PlGF is known to improve cardiac performance by promoting cardiomyocyte survival and cardiomyogenesis via recruitment of bone marrow-derived progenitor cells towards infarcted myocardial tissue \[[@pone.0147686.ref022]\]. Hypoxia is an important stimulus of PlGF expression, and hypoxia inducible factor-1-alpha (HIF-1α) can directly activate its transcription \[[@pone.0147686.ref010];[@pone.0147686.ref013]\]. High PlGF release typically accompanies acute ischemia and infarction, but elevated levels may reflect underlying acute or chronic hypoxia. Our results demonstrate that OSA is an important determinant of PlGF levels in patients with ACS. Among several confounding factors, OSA seems to mediate a portion of the release of PlGF detected in these patients. In line with this data, PlGF may represent a valuable marker of OSA in patients suspected of having acute coronary syndrome. Furthermore, the presence of OSA may affect the prognostic value of PlGF levels, and this possibility should be considered in studies in which PlGF is used as a clinical biomarker for risk stratification.

There is evidence that OSA may be associated with the activation of cardiovascular adaptive mechanisms. Berger et al reported that the numbers of endothelial progenitor cells are elevated and that angiogenesis increases in patients with AMI and coexistent OSA compared with patients with AMI without OSA \[[@pone.0147686.ref006]\]. EPCs are mobilized by signaling pathways, such as the HIF-1α pathway, which are also activated in OSA \[[@pone.0147686.ref023]\] \[[@pone.0147686.ref024]\]. HIF-1α stimulates the production of VEGF, and several studies have shown that patients with OSA have increased levels of VEGF \[[@pone.0147686.ref025]\]. In contrast, another study found that although VEGF expression in monocytes was found to be higher in patients with AMI and OSA compared with patients with AMI without OSA, no difference was reported for plasma VEGF levels between these groups \[[@pone.0147686.ref006]\]. On the other hand, earlier studies, which demonstrated that PlGF levels at presentation are of prognostic value for clinical outcomes in patients with ACS, did not find any correlation between PlGF levels and VEGF levels \[[@pone.0147686.ref012]\]. Thus far, the effect of OSA on plasma PlGF levels after ACS has not been investigated. In patients with ACS, plasma levels of PlGF increase acutely and transiently \[[@pone.0147686.ref012]\]. A single initial measurement of a patient's plasma PlGF level appears to extend the predictive and prognostic information gained from traditional risk markers \[[@pone.0147686.ref026]\]. The extent to which PlGF levels are elevated is influenced by the severity of myocardial damage, and the overall effects of PlGF may vary with disease status and comorbidities \[[@pone.0147686.ref027]--[@pone.0147686.ref029]\]. In this sense, OSA could be essential and may mediate a portion of the prognostic impact of PlGF, given the relationship between PlGF levels after ACS and OSA that was observed in our study. However, it is known that OSA increases the incidence of morning peak of onset in acute myocardial infarction. Despite the fact that there are no data on whether PlGF has a diurnal pattern of variation, a perturbation in circadian PlGF balance might be a possible contributor to the onset of MI \[[@pone.0147686.ref030];[@pone.0147686.ref031]\]. Furthermore, elevated PlGF levels may reflect underlying acute or chronic hypoxia. PlGF has potent angiogenic properties, especially under pathological circumstances, and increased PlGF levels could counteract the damaging effects of ischemia \[[@pone.0147686.ref021]\]. Iwama et al observed that patients with higher plasma PlGF levels on day 3 after AMI showed greater improvement in left ventricular ejection fraction (LEVF) during the chronic phase (6 months post MI) than did patients with lower plasma PlGF levels, and they also observed that patients with improvement in LEVF in the chronic phase had significantly higher plasma levels of PlGF in the acute phase compared with patients without improvement; these findings suggest that PlGF may be involved in repairing injured myocardial tissue \[[@pone.0147686.ref013]\]. In addition, experimental studies have demonstrated that PlGF may serve both as a marker of adaptive cardiac remodeling and as a promising novel therapeutic agent for revascularizing and regenerating the infarcted myocardium and for improving its performance after MI \[[@pone.0147686.ref014];[@pone.0147686.ref022]\]. Consistent with these findings, it is possible that the elevated levels of PlGF detected in the group of patients with OSA could exert a beneficial effect that could promote long-term improvement in cardiac function after ACS in these patients.

Limitations {#sec014}
-----------

This study has several limitations. First, we excluded patients with daytime sleepiness, which were the patients who exhibited the most severe OSA. Second, OSA was diagnosed based on respiratory polygraphy, which could underestimate the severity of OSA. Third, the high variability in PlGF levels detected both in controls and patients may limit its usefulness. On the other hand, this study was performed only for patients with ACS. Previous clinical studies including subjects without ACS showed PlGF mean plasma levels of 10 pg/mL \[[@pone.0147686.ref013]\] and 16.6 pg/mL \[[@pone.0147686.ref031]\], both of them lower than in our ACS patients groups, either with or without OSA. Ideally, longitudinal studies measuring PlGF at the time of diagnosis of OSA would add to the verification of PlGF as a biomarker. Fourth, alternative noninvasive biomarkers of cardiac dysfunction, such as the brain natriuretic peptide (BNP), were not assessed. As reported elsewhere, PlGF and BNP levels are known to positively correlate in patients with ischemic cardiomyopathy \[[@pone.0147686.ref032]\]. This demonstrates an increase of PlGF with the severity of heart failure in such patients, regardless of OSA. Finally, the design of this study does not allow us to evaluate the long-term prognostic role of PlGF in OSA or to draw definitive conclusions.

Conclusions {#sec015}
===========

The results of this study show that in patients with ACS, elevated plasma levels of PlGF are associated with the presence of OSA and with adverse outcomes during short-term follow-up. These findings suggest that different pathophysiological mechanisms might affect the cardiac expression of PlGF after ischemic injury, as well as their predictive role in patients with and without OSA.
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ACS

:   Acute coronary syndrome

AHI

:   Apnea-hypopnea index

CPAP

:   Continuous positive airway pressure

AMI

:   Acute myocardial infarction

ESS

:   Epworth sleepiness scale

BMI

:   Body mass index

CU

:   Coronary unit

CV

:   Cardiovascular

ODI

:   Oxygen desaturation index

OSA

:   Obstructive sleep apnea

MI

:   Myocardial infarction

PlGF

:   Placental growth factor

SaO2

:   Oxygen saturation

OR

:   odds ratio

STEMI

:   ST segment elevation myocardial infarction

VEGF

:   Vascular endothelial growth factor
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